http://www.congoo.com/feed/newschannelsfeed.aspx?chid=22&catid=156News Feed for - Pharmaceutical-Industryhttp://www.congoo.com/news/addstorycomment.aspx?st=239837141&Channel_ID=22&Category_ID=1562013-06-19T11:53:00/PRNewswire via COMTEX/ -- Amerivet Solutions, LLC (AMERIVET), a unique sourcing company servicing all branches of government from Federal to Municipal, is pleased to announce that they have expanded TMC Nethttp://www.congoo.com/news/addstorycomment.aspx?st=239841810&Channel_ID=22&Category_ID=1562013-06-19T12:32:00PR Newswire NESS ZIONA, Israel, June 19, 2013 NESS ZIONA, Israel, June 19, 2013 /PRNewswire/ --NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239841797&Channel_ID=22&Category_ID=1562013-06-19T12:31:00Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 19, 2013 NEW YORK, June 19, 2013 /PRNewswire/ --Today, Wall Street Reports announced new research Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239818131&Channel_ID=22&Category_ID=1562013-06-19T09:21:00Highly sensitive and accurate test detects cancer-related microRNA in blood of patients even before the development of colorectal cancer DALLAS, June 19, 2013 /PRNewswire-USNewswire/ --? A new blood KGWN TVhttp://www.congoo.com/news/addstorycomment.aspx?st=239827854&Channel_ID=22&Category_ID=1562013-06-19T10:08:00A renowned Toronto researcher and a U.S. colleague have unveiled a new "sharpshooter" drug that they say could provide a breakthrough in inhibiting the growth of a variety of cancers. Dr. Tak Mak, an Woodstock Sentinel-Reviewhttp://www.congoo.com/news/addstorycomment.aspx?st=239838866&Channel_ID=22&Category_ID=1562013-06-19T11:57:00Astellas Pharma Inc. (www.astellas.com), a pharmaceutical company dedicated to improving the health of people around the world through innovative and reliable pharmaceutical products, has joined SAFE-BioPharma Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239847888&Channel_ID=22&Category_ID=1562013-06-19T12:45:00PR Newswire LOS ANGELES, June 19, 2013 LOS ANGELES, June 19, 2013 /PRNewswire/ -- Kinney Drugs, a leading community pharmacy and healthcare services company in New York and Vermont, is targeting the Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=238643654&Channel_ID=22&Category_ID=1562013-06-19T10:46:00FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED) DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239825189&Channel_ID=22&Category_ID=1562013-06-19T09:56:00H. Lundbeck A/S (LUN), the Nordic region's second-largest drugmaker, was fined 93.8 million euros ($125.6 million) by the European Union over agreements with other companies that held back sales of cheaper Bloomberghttp://www.congoo.com/news/addstorycomment.aspx?st=239843660&Channel_ID=22&Category_ID=1562013-06-19T12:18:00PHILADELPHIA--(BUSINESS WIRE)-- Iroko Pharmaceuticals Inc. (www.iroko.com), announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial CNBChttp://www.congoo.com/news/addstorycomment.aspx?st=239847852&Channel_ID=22&Category_ID=1562013-06-19T12:40:00CONTACT: ChemoCentryx: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 investor@chemocentryx.com Media: Susan Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239847886&Channel_ID=22&Category_ID=1562013-06-19T12:37:00/PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it has received conditional approval of Sys-Con Indiahttp://www.congoo.com/news/addstorycomment.aspx?st=239841622&Channel_ID=22&Category_ID=1562013-06-19T12:31:00CONTACT: For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 Dianne@elitepharma.com www.elitepharma.comReutershttp://www.congoo.com/news/addstorycomment.aspx?st=239847732&Channel_ID=22&Category_ID=1562013-06-19T12:40:00Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that Howard J. Weisman has been appointed to the company's Reutershttp://www.congoo.com/news/addstorycomment.aspx?st=239547690&Channel_ID=22&Category_ID=1562013-06-19T12:24:001:25am BST Intercept Pharmaceuticals Inc announced the pricing of an underwritten public offering of 1,730,000 shares of its common stock at a public offering price of $33.01 per share. In addition, Intercept Reuters UKhttp://www.congoo.com/news/addstorycomment.aspx?st=239847703&Channel_ID=22&Category_ID=1562013-06-19T12:49:00(GLOBE NEWSWIRE) -- Biodel Inc. (BIOD) today announced the pricing of an underwritten public offering of 4,482,760 shares of its common stock at a public offering price of $4.35 per share. All of the Yahoo! Financehttp://www.congoo.com/news/addstorycomment.aspx?st=239837391&Channel_ID=22&Category_ID=1562013-06-19T11:47:00Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's CNBChttp://www.congoo.com/news/addstorycomment.aspx?st=239845790&Channel_ID=22&Category_ID=1562013-06-19T12:32:00has suffered another drug trial setback.Its diabetes drug Onglyza, developed with Bristol-Myers Squibb, failed to reduce heart risks or strokes in a large scale clinical trial. Despite investor hopes, Argentina Starhttp://www.congoo.com/news/addstorycomment.aspx?st=239839991&Channel_ID=22&Category_ID=1562013-06-19T12:18:00- Sunshine Biopharma Inc. (OTCQB "Sunshine Biopharma is not in the business of patenting human genes or copies thereof, such as cDNA.? We patent small molecules for use as chemotherapeutics in the treatment Yahoo! Financehttp://www.congoo.com/news/addstorycomment.aspx?st=239848852&Channel_ID=22&Category_ID=1562013-06-19T12:45:00Marathon Patent Group Inc. (MARA)'s Relay IP unit said it filed 10 patent infringement cases in federal court in Delaware June 14. All the cases alleged infringement of patent 5,331,637. The patent, Bloomberghttp://www.congoo.com/news/addstorycomment.aspx?st=239844468&Channel_ID=22&Category_ID=1562013-06-19T12:24:006:02am BST Newron Pharmaceuticals SpA announced the Safinamide Phase III study results. Results presented showed that in the SETTLE study safinamide significantly improved "responder" rates in fluctuating Reuters UKhttp://www.congoo.com/news/addstorycomment.aspx?st=239844467&Channel_ID=22&Category_ID=1562013-06-19T12:24:006:02am BST Newron Pharmaceuticals SpA announced that sNN0031 proved safety and initial efficacy in Phase I/II study in Parkinson's disease. In the study, 12 patients with Idiopathic Parkinson's disease Reuters UKhttp://www.congoo.com/news/addstorycomment.aspx?st=239844410&Channel_ID=22&Category_ID=1562013-06-19T12:24:00Sunshine Biopharma Inc. (SBFM.OB), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced that its operations RTTNews.comhttp://www.congoo.com/news/addstorycomment.aspx?st=239843633&Channel_ID=22&Category_ID=1562013-06-19T12:10:00By Mina Marmor and Henry I. Miller The relatively obscure liver inflammation caused by hepatitis C virus (HCV) is a significant threat worldwide, and its prevalence is growing. It demands greater attention Forbes.comhttp://www.congoo.com/news/addstorycomment.aspx?st=239840608&Channel_ID=22&Category_ID=1562013-06-19T12:04:00A team of Canadian and U.S. researchers has developed a new "sharp-shooter" drug they hope may be a breakthrough in treating several types of aggressive cancer. The drug, known for now as CFI-400945, CBC